Ogivri is the biosimilar version of Swiss drug maker Roches Herceptin, a breast cancer and gastric cancer drug with sales of $6.9 billion a year worldwide

Ogivri (Trastuzumab), jointly developed by Biocon and Mylan, is the biosimilar version of Swiss drug maker Roche's Herceptin.

The competition to tap large molecule structured complex bio-similars or off-patent biotech drugs is heating up.

India has taken a lead here and going by the official figures, there are around 24 cancer biosimilar drugs in all that have already been approved by the Indian regulator since 2011.

Indian drug makers are slugging it out with Big Pharma over launch of biosimilars. Will they be able to hold their fort in this emerging space?

Stocks and oil have been strongly correlated in recent months as crude prices tanked to decade lows, and their movements in opposite directions during the session was notable to investors.

There is pressure by some sections within the US to downgrade India from 'watch list' to 'Priority foreign country'.

The profit for the second quarter period crossed Rs 700 crore. According to analysts, these were a good set of numbers given the challenges and the fact that it did not take any price hikes.

The exclusive rights for this product are applicable for the US, Canada, India, Russia and the CIS, Australia, New Zealand and Venezuela.

Drug Controller General Dr GN Singh directed officials to compile list of veterinary drugs with details like date of approval, name of manufacturer, composition of product and its storage conditions.

It is still not clear who is severely impacted by the ban. Because if the impact was huge on any company, it would have by now informed the stock exchanges.

Under the terms of the collaboration, Dr Reddy's shall undertake a full range of regulatory and commercial services to seek approval and launch the three drugs - Kyprolis, Blincyto and Repatha - in India.

Under the terms of the collaboration, Dr Reddy's shall undertake a full range of regulatory and commercial services to seek approval and launch the three drugs - Kyprolis, Blincyto and Repatha - in India

Epirus Biopharmaceuticals said that the domestic drug regulator has approved its copy of a top-selling arthritis treatment, paving the way for its launch in the India early next year.

Ten years ago this month, the dotcom bust began, burning trillions of dollars and millions of dreams. BT asks two entrepreneurs who were there for the lessons they learnt.

From the first week of October, frequent visitors would have begun to notice subtle changes at the 25-acre headquarters of Biocon, India’s best known biotech company.